Boehringer Ingelheim cancer drug shows positive results in Phase III trial - Pharmaceutical Technology
Docetaxel plus nintedanib versus docetaxel plus placebo in patients with previously treated non-small-cell lung cancer (LUME-Lung 1): a phase 3, double-blind, randomised controlled trial - The Lancet Oncology
VARGATEF (nintedanib) - Safety Profile | Boehringer Ingelheim
Investigation of biomarkers in patients with adenocarcinoma of the lung receiving nintedanib according to approved label: Non-in
JPM | Free Full-Text | Diagnostic, Predictive, and Prognostic Biomarkers in Non-Small Cell Lung Cancer (NSCLC) Management
Non-interventional LUME-BioNIS study of nintedanib plus docetaxel after chemotherapy in adenocarcinoma non-small cell lung cancer: A subgroup analysis in patients with prior immunotherapy - ScienceDirect
Lume-Lung 1: study design. NSCLC, non-small cell lung cancer. | Download Scientific Diagram
Lume-Lung 1: study design. NSCLC, non-small cell lung cancer. | Download Scientific Diagram
Asco – Boehringer's qualified success in lung cancer | Evaluate
Docetaxel plus nintedanib versus docetaxel plus placebo in patients with previously treated non-small-cell lung cancer (LUME-Lung 1): a phase 3, double-blind, randomised controlled trial - The Lancet Oncology
Nintedanib plus docetaxel after progression on immune checkpoint inhibitor therapy: insights from VARGADO, a prospective study in patients with lung adenocarcinoma | Future Oncology
Analysis of patient-reported outcomes from the LUME-Lung 1 trial: A randomised, double-blind, placebo-controlled, Phase III study of second-line nintedanib in patients with advanced non-small cell lung cancer - ScienceDirect
Docetaxel plus nintedanib versus docetaxel plus placebo in patients with previously treated non-small-cell lung cancer (LUME-Lung 1): a phase 3, double-blind, randomised controlled trial - The Lancet Oncology
Articles Docetaxel plus nintedanib versus docetaxel plus placebo in patients with previously treated non-small-cell lung cancer
Visor Redalyc - Nintedanib in combination with docetaxel for second-line treatment of advanced non-small-cell lung cancer; GENESIS-SEFH drug evaluation reporta
Indication | Uses | VARGATEF® (nintedanib)
Time since start of first-line therapy as a predictive clinical marker for nintedanib in patients with previously treated non-sm
Collective teaching of transverse flute as a component of a pulmonary rehabilitation program: An innovative study
Nintedanib + docetaxel after immunotherapy in adenocarcinoma non-small cell lung cancer: first results from the non-intervention
Nintedanib in combination with docetaxel for second-line treatment of advanced non-small-cell lung cancer; GENESIS-SEFH drug evaluation reporta
Il Paziente senza target - ppt video online download
studio LUME-Lung 1 Archivi • NCF - Notiziario Chimico Farmaceutico
Kaplan–Meier analysis of PFS and OS in patients with advanced non-small cell lung cancer with adenocarcinoma histology with time since start of first-line. - ppt download
Docetaxel plus nintedanib versus docetaxel plus placebo in patients with previously treated non-small-cell lung cancer (LUME-Lung 1): a phase 3, double-blind, randomised controlled trial - The Lancet Oncology
Tumor growth over time: analysis of data from the LUME-Lung 1 trial
Non-interventional LUME-BioNIS study of nintedanib plus docetaxel after chemotherapy in adenocarcinoma non-small cell lung cancer: A subgroup analysis in patients with prior immunotherapy - ScienceDirect
